Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naltrexone delayed release - Aardvark Therapeutics

Next Previous
Drug Profile

Naltrexone delayed release - Aardvark Therapeutics

Alternative Names: ARD-301; DBR-LDN; delayed-release naltrexone hydrochloride; SP 104

Latest Information Update: 07 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aardvark Therapeutics
  • Developer Aardvark Therapeutics; Sorrento Therapeutics
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Fibromyalgia
  • No development reported Pain
  • Discontinued Post acute COVID 19 syndrome

Most Recent Events

  • 07 Jan 2025 Chemical structure information added.
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Fibromyalgia(In volunteers) in New Zealand (PO, Capsule)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Pain(In volunteers) in New Zealand (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top